Evidence map›Paper›PMID 30577391›Full record

ArticleThe Journal of urology2019

Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.

Ciro Franzese, Davide Franceschini, Lucia Di Brina, Giuseppe Roberto DʼAgostino, Pierina Navarria, Tiziana Comito, Pietro Mancosu, Stefano Tomatis, Marta Scorsetti

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ciro FranzeseRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Davide FranceschiniRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Lucia Di BrinaRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Giuseppe Roberto DʼAgostinoRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Pierina NavarriaRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Tiziana ComitoRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Pietro MancosuRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Stefano TomatisRadiotherapy and Radiosurgery Unit, Humanitas Clinical and Research Center, Milan, Italy.
Marta ScorsettiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeKidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND

methodsA total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3.

resultsAll patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases.

conclusionsStereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Renal CellFemaleFollow-Up StudiesHumansIncidenceKidneyKidney NeoplasmsLung NeoplasmsLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm Recurrence, Local

Identifiers

PMID30577391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.